Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

FDA Panel Shows Support for Epoetin Biosimilar

December 30, 2021

The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 14-1 to recommend approval of an epoetin alfa biosimilar agent. If approved by the FDA, this would be the first erythropoiesis-stimulating biosimilar agent.

ODAC's decision was based on demonstrated efficacy compared with the reference product, and approval would apply to all of the FDA-approved indications for epoetin alfa, including:
treatment of anemia resulting from:

  • chronic kidney disease in patients on and not on dialysis
  • zidovudine in HIV-infected patients
  • the effects of concomitant myelosuppressive chemotherapy
  • reduction of allogeneic red blood cell transfusions in patients undergoing elective, non-cardiac, non-vascular surgery

Pfizer, the manufacturer of the biosimilar agent under review, is in the midst of a legal battle with Amgen, the manufacturer of the reference product, which claims that Pfizer provided its marketing notice for the biosimilar too early. Based on agreed-upon stipulations, makers of biosimilar products must provide 180-day marketing notices after FDA approval. This case is set to begin in September.

Sources: Pfizer press release, May 25, 2017; Pharma Times, May 26, 2017.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals